This lawsuit was filed in February of 2009 and gives an excellent history of NSF:
26. This is a personal injury claim relating to Eric Jenkins' development of, and subsequent death from, Nephrogenic Systemic Fibrosis ("NSF"), also known as Nephrogenic Fibrosing Dermopathy ("NFD").
27. NSF/NFD develops only in patients with renal insufficiency, such as Eric Jenkins, who have been given an injection of a gadolinium-based contrast agent such as Magnevist, Omniscan, OptiMARK, and/or upon information and belief, MultiHance and/or ProHance.
28. NSF/NFD is predominantly characterized by discoloration, thickening, tightening, and swelling of the skin within weeks after receiving a gadolinium -based contrast injection such as Magnevist, Omiscan, OptiMARK and/or upon information and belief, MultiHance and/or ProHance.
29. These symptoms can occur weeks or months after a person is administered these dyes.
30. These fibrotic and edematous changes produce muscular weakness and inhibit flexion and extension of joints, resulting in painful and disfiguring contractures.
31. NSF/NFD often progresses to painful inhibition of the ability to use the arms, legs, hands, feet, and other joints.
32. The skin changes that begin as darkened patches or plaques progress to a "woody" texture, and are accompanied by burning, itching, or severe pain in the areas of involvement.
33. NSF/NFD also progresses to a fibrotic or scarring condition of other body organs such as the lungs, heart, liver, and musculature, and that can inhibit their ability to function properly and may lead to death.
34. NSF/NFD is a progressive disease for which there is no known cure.
35. NSF/NFD has been reported in medical literature since 2000.
36. It has always been the case that this clinical entity now known as NSF/NFD develops in patients with renal insufficiency, who have been given an injection of gadolinium-based contrast agent such as Omniscan, Magnevist, OptiMARK, MultiHance, and/or ProHance.